Compare PCRX & NAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | NAT |
|---|---|---|
| Founded | 2006 | 1995 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 825.8M |
| IPO Year | 2011 | 1997 |
| Metric | PCRX | NAT |
|---|---|---|
| Price | $20.56 | $4.05 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $35.33 | $3.25 |
| AVG Volume (30 Days) | 1.0M | ★ 3.1M |
| Earning Date | 02-26-2026 | 02-27-2026 |
| Dividend Yield | N/A | ★ 8.42% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.47 | 0.01 |
| Revenue | ★ $716,791,000.00 | $294,820,000.00 |
| Revenue This Year | $6.21 | N/A |
| Revenue Next Year | $8.26 | $24.97 |
| P/E Ratio | ★ $43.50 | $448.83 |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $18.80 | $2.13 |
| 52 Week High | $27.64 | $4.23 |
| Indicator | PCRX | NAT |
|---|---|---|
| Relative Strength Index (RSI) | 36.14 | 68.04 |
| Support Level | $18.80 | $3.96 |
| Resistance Level | $21.12 | $4.19 |
| Average True Range (ATR) | 1.25 | 0.13 |
| MACD | -0.33 | 0.02 |
| Stochastic Oscillator | 22.98 | 77.91 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Nordic American Tankers Ltd owns and operates double-hull crude oil tankers. It is an international tanker company that owns double-hull Suezmax tankers. It operates vessels in the spot market or on spot market-related charters according to cooperative arrangements with third parties. The company's fleet consists of crude oil tankers, and all of its vessels are employed in the spot market. The company has only one type of vessel - Suezmax crude oil tankers. It operates in markets that are very competitive and based mainly on supply and demand.